Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Barriers to SGLT2 inhibitor prescribing in primary care: findings from a cross-sectional questionnaire study in England.

Clinical kidney journal·2026
Same author

Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology.

Kidney international reports·2026
Same author

Correction: Association and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study.

PloS one·2026
Same author

Anti-glomerular basement membrane disease-treatment standard.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Human neutrophil-derived extracellular vesicles induce renal endothelial inflammation in critical illness: an ex vivo investigation.

British journal of anaesthesia·2025
Same author

Long-Term Follow-Up of a Glucocorticoid Minimizing Regimen for the Treatment of Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.

Kidney international reports·2025
Same journal

NRP1 transport of cancer therapeutics mediated by tumor-penetrating peptides.

Drugs of the future·2017
Same journal

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Drugs of the future·2016
Same journal

Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.

Drugs of the future·2015
Same journal

SGI-110: DNA Methyltransferase Inhibitor Oncolytic.

Drugs of the future·2015
Same journal

Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Drugs of the future·2015
Same journal

Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.

Drugs of the future·2015
See all related articles

Related Experiment Video

Updated: May 15, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Fostamatinib Disodium.

Stephen P McAdoo1, Frederick W K Tam

  • 1Imperial College Kidney and Transplant Institute, London UK.

Drugs of the Future
|January 4, 2013
PubMed
Summary
This summary is machine-generated.

Fostamatinib disodium, a Syk inhibitor, shows promise for treating autoimmune and malignant diseases. Clinical trials indicate efficacy in rheumatoid arthritis and other conditions, suggesting broad therapeutic potential.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Experiment Videos

Last Updated: May 15, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Area of Science:

  • Immunology
  • Pharmacology
  • Biochemistry

Background:

  • Non-receptor tyrosine kinase Syk is crucial for immune cell signaling via B cell and Fc receptors.
  • Syk plays a role in autoimmune, allergic, and malignant diseases, making it a therapeutic target.

Purpose of the Study:

  • To evaluate the therapeutic potential of Fostamatinib disodium, an orally bioavailable Syk inhibitor.
  • To review the in vitro and in vivo efficacy of Fostamatinib disodium (R406) in various disease models.

Main Methods:

  • In vitro studies assessing Syk inhibition in cell types.
  • In vivo studies using animal models for asthma, arthritis, lupus, glomerulonephritis, diabetes, and lymphoma.
  • Review of clinical trial data from Phase II and III studies.

Main Results:

  • Fostamatinib disodium (R406) demonstrated efficacy across multiple animal models of human diseases.
  • Phase II trials showed promise in autoimmune thrombocytopenia, lymphoma, and rheumatoid arthritis.
  • Ongoing Phase III trials for rheumatoid arthritis are in progress.

Conclusions:

  • Fostamatinib disodium exhibits broad therapeutic potential for various autoimmune, allergic, and malignant conditions.
  • Despite potential toxicities from Syk inhibition, current data support Fostamatinib's future clinical use.
  • Further clinical evaluation is warranted for Fostamatinib in diverse human diseases.